Will Patients Benefit from Regionalization of Gynecologic Cancer Care?

Kathleen F. Brookfield¹, Michael C. Cheung², Relin Yang², Margaret M. Byrne³, Leonidas G. Koniaris²*

¹Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Miami, Florida, United States of America, ²DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, United States of America, ³Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida, United States of America

Abstract

Objective: Patient chances for cure and palliation for a variety of malignancies may be greatly affected by the care provided by a treating hospital. We sought to determine the effect of volume and teaching status on patient outcomes for five gynecologic malignancies: endometrial, cervical, ovarian and vulvar carcinoma and uterine sarcoma.

Methods: The Florida Cancer Data System dataset was queried for all patients undergoing treatment for gynecologic cancers from 1990–2000.

Results: Overall, 48,981 patients with gynecologic malignancies were identified. Endometrial tumors were the most common, representing 43.2% of the entire cohort, followed by ovarian cancer (30.9%), cervical cancer (20.8%), vulvar cancer (4.6%), and uterine sarcoma (0.5%). By univariate analysis, although patients treated at high volume centers (HVC) were significantly younger, they benefited from an improved short-term (30-day and/or 90-day) survival for cervical, ovarian and endometrial cancers. Multivariate analysis (MVA), however, failed to demonstrate significant survival benefit for gynecologic cancer patients treated at teaching facilities (TF) or HVC. Significant prognostic factors at presentation by MVA were age over 65 (HR = 2.6, p<0.01), African-American race (HR = 1.36, p<0.01), and advanced stage (regional HR = 2.08, p<0.01; advanced HR = 3.82, p<0.01, respectively). Surgery and use of chemotherapy were each significantly associated with improved survival.

Conclusion: No difference in patient survival was observed for any gynecologic malignancy based upon treating hospital teaching or volume status. Although instances of improved outcomes may occur, overall further regionalization would not appear to significantly improve patient survival.

Introduction

To date, studies on the relationship between survival and hospital volume and teaching status for gynecologic malignancies have focused primarily on ovarian cancer.[1,2,3,4,5,6,7,8,9,10] A systematic review of the effect of specialized care for ovarian cancer patients found no demonstrable benefit by surgeon specialty for earlier stages of disease, but that surgery by a gynecologic oncologist resulted in a 5 to 8 month median survival benefit for patients with advanced stage disease.[9,11] Similar findings have been reported by studies conducted outside the United States.[2] More recently, however, data from the National Cancer Institutes (NCI) Surveillance Epidemiology and End Results (SEER)-linked Medicare database suggests no benefit for ovarian cancer treated by gynecologists versus gynecological oncologist.[12] As well, SEER-linked Medicare has been used to demonstrate similar outcomes for the use of chemotherapy when administered by medical oncologists or gynecologic oncologists.[13]

Similar to the more recent studies in ovarian cancer, studies investigating optimal treatment paradigms for early-stage endometrial cancer have found minimal differences in outcomes between general gynecologists and gynecologic oncologists.[14,15] Studies on advanced stage endometrial cancer patients, focused on hospital volume, have suggested a potential survival benefit for certain subsets of patients, such as the elderly, treated at high-volume centers.[16,17] To date, the effects of center volume or teaching status on outcomes of patient with cervical or vulvar cancers or uterine sarcomas have not been reported in the literature.

In contrast to SEER-linked Medicare data, treatment information, including chemotherapy, can be determined for all patients by treating facility in the Florida Cancer Data System (FCDS), which is well validated in determining outcome disparities and treatment differences by center volume or teaching status.[18,19,20,21,22,23] We therefore examined the FCDS to provide insight into the entire field of gynecological oncology by examination the major gynecologic malignancies - cervical, ovarian, endometrial, uterine sarcoma, and vulvar cancers - with the hope of evaluating the role of treatment facility on patient outcomes.

Methods

The 2007 FCDS data set was used to identify all incident cases of cervical, ovarian, endometrial and vulvar malignancies and
uterine sarcomas diagnosed in the state of Florida from 1990–2000. A total of 48,981 cases of gynecological cancer were extracted for analysis (Figure 1). Cases with missing information for any key variable, duplicate cases, carcinomas in situ, and cases treated by community physicians independent of the hospital or ambulatory care center settings were excluded from the univariate analysis. Incident vulvar carcinoma and uterine sarcoma cases were analyzed; however, case numbers were too small to establish a meaningful interpretation of the univariate five-year survival data. These two gynecological malignancies are described by demographic, social and clinical characteristics, and are included in the multivariate logistic regression analysis, which was performed after combining all types of gynecologic cancers.

Medical facilities were defined as TFs or non-teaching facilities (NTF) based on recognition as a teaching institution by the Association of American Medical Colleges (AAMC). There are currently 11 AAMC-recognized TFs in the state of Florida. The data from FCDS were tabulated to determine the number of treated cancers and surgical resections for five gynecologic cancer types (cervical, ovarian, endometrial, vulvar, and uterine sarcoma) performed at each institution in the state of Florida during the study period.

Medical facilities were grouped into tertiles based on number of surgeries with curative intent performed during the study period. The upper one-third of institutions was classified as HVC, the middle one-third as intermediate-volume centers (IVC), and the lower one-third as low-volume centers (LVC). The definitions of HVC, IVC, and LVC for cervical, ovarian, endometrial and vulvar cancers are shown in Figure 1. For uterine sarcoma, HVCs operated on an average of 5 cases in the 10-year study period, IVCs operated on an average of 3 cases in the 10-year study period, and LVCs operated on an average 1 case in the 10-year study period.

The staging criteria used by the FCDS are consistent with the Surveillance, Epidemiology, and End Result (SEER, National Cancer Institute) summary staging and differ from the International Federation of Gynecology and Obstetrics (FIGO) staging guidelines. In this study, local staging represents disease that does not extend beyond the primary organ, while those having positive lymph nodes at the time of resection were classified as having regional disease. Documentation of distant metastases during the peri-operative period led to classification of affected patients as having distant disease.

Statistical computations were performed with SPSS version 15.0 for univariate analyses and the final multivariate regression was corrected for clustering in facilities using STATA version 8.0. The chi-square test was used for group comparisons of categorical variables and ANOVA was used for group comparisons of

---

**Figure 1.** Flow diagram depicting number of incident gynecologic malignancies diagnosed in the state of Florida from 1990–2000. doi:10.1371/journal.pone.0004049.g001
continuous variables. Overall survival was used in lieu of disease-specific survival because the FCDS database contains information only on the primary cause of death. Overall survival was calculated by subtracting the date of death or date of last contact from the time of the initial diagnosis. Site-specific thirty-day and ninety-day survival rates, and five-year survival rates were calculated using the Kaplan-Meier method. Univariate Cox proportional hazards regression was used to identify demographic variables and disease characteristics significantly associated with survival.

Significant variables from the univariate analysis were included in the multivariate regression analysis to determine whether facility characteristics were associated with survival for all gynecologic malignancies. Data on lymph nodes included the number of lymph nodes dissected and whether or not lymph nodes were positive for malignant cells. Due to the co-linearity of these variables, only one of these variables can be entered as a covariate in the final multivariate regression model. We chose to enter the variable depicting number of lymph nodes dissected, as we felt this is a better marker of the extent of surgical intervention undertaken at HVCs and TFs compared to LVCs and NTFs. Tumor histology and stage were covariates entered into the final model to reflect severity of disease.

**Results**

**Treatment at a teaching facility versus a non-teaching facility**

**Patient demographic, social, and clinical characteristics.** Over the ten-year period studied, 10,175 patients with cervical cancer, 15,131 patients with ovarian cancer, 21,149 patients with endometrial cancer, 2,737 patients with vulvar cancer, and 253 patients with uterine sarcoma were identified. Demographics, social and clinical characteristics of the entire study population treated at TFs and NTFs are summarized in Table 1. The majority of patients in the cohort were Caucasian (n = 43,653, 89.1%) and non-Hispanic (n = 43,901, 89.6%). For cervical, ovarian, and endometrial cancers, patients were treated more frequently at NTFs, and those individuals who were treated at TFs were significantly younger than those treated at NTFs. Regional and distant disease were more commonly treated at teaching facilities, whereas gynecologic cancer treated at non-teaching facilities was more commonly localized disease.

**Survival.** Kaplan-Meier plots comparing overall survival at TF and NTF are shown in Figure 2 for (a) cervical cancer, (b) ovarian cancer, (c) endometrial cancer, (d) uterine sarcoma, and (e) vulvar cancer. Five-year survival rates for patients diagnosed with cervical, ovarian and endometrial cancer at HVCs, IVCs and LVCs are summarized in Table 2. For cervical cancer, five-year survival rates were significantly greater for patients treated at HVCs compared to those treated at IVCs or LVCs (64% versus 61.3% versus 59.5%; p<0.01). Thirty-day and ninety-day surgical mortality rates were significantly lower for patients treated at HVCs, compared to IVCs or LVCs (p<0.01).

For ovarian cancer, univariate analysis showed that 5-year survival rates were significantly greater for patients treated at HVCs compared to those treated at IVCs or LVCs (42.2% versus 40.4% versus 36.2%; p<0.01). Thirty-day and 90-day surgical mortality rates were significantly lower for patients treated at HVCs compared to IVCs or LVCs. For endometrial cancer, univariate analysis demonstrated 5-year survival rates were significantly greater for patients treated at IVCs compared to HVCs. Thirty-day surgical mortality rates were significantly lower for patients treated at HVCs compared to IVCs or LVCs.

**Multivariate Analysis.** Results of the multivariate analysis including all five gynecologic malignancies using a Cox regression model adjusted for clustering effects are summarized in Table 3. Cox regression models adjusting for clustering effects were also created separately for each malignancy, with no difference in survival seen for patients treated at TFs versus NTFs, or HVCs versus LVCs. An abbreviated regression model for each cancer type is shown in Table 4. TF status and hospital volume status were not significant predictors of survival for gynecologic malignancy. Independent predictors of survival for all gynecologic malignancies studied in the 10-year period were diagnosis of ovarian cancer, age >40 years, African-American race, Medicaid payer status, lymph node examination, tumor stage, tumor grade, surgical extirpation, chemotherapy treatment, and lack of radiation therapy.

Compared to patients diagnosed with cervical cancer, ovarian cancer patients had a 13% increased risk of death over the 10-year study period. Gynecologic cancer patients aged 41-65 years had a 52% increased risk of death (HR = 1.52, p<0.01) and patients older than 65 years had a 261% increased risk of death (HR = 2.61, p<0.01) compared to patients younger than 40 years. African-American patients diagnosed with gynecologic malignancies were 36% more likely to die (HR = 1.36, p<0.01) in the 10-year study period compared to Caucasian patients. Medicaid patients were 29% more likely to die from a gynecologic malignancy in the 10-year study period (HR = 1.29, p<0.01) compared to privately insured patients. A decreased risk of death from gynecologic malignancy was found when lymph nodes were examined compared to when they were not examined. This effect...
Table 1. Demographic, Social, and Clinical Characteristics of the Study Group.

|                          | Cervical | Ovarian | Endometrial |
|--------------------------|----------|---------|-------------|
|                          | Overall  | Facility | Hospital Volume | Overall  | Facility | Hospital Volume | Overall  | Facility | Hospital Volume |
|                          | TF NTF p | HVC IVC LVC p | TF NTF p | HVC IVC LVC p | TF NTF p | HVC IVC LVC p |
| Median age at diagnosis (years) | 51.9 48.2 53.2 <0.01 | 48.7 51.9 55.3 <0.01 | 643 59.3 65.1 <0.01 | 62.2 64.7 65.8 <0.01 | 66.7 63.1 67.2 <0.01 | 65.6 66.9 67.5 <0.01 |
| n % of total             | 10,175 26.7 73.3 | 15,131 14.2 85.8 | 21,149 12 88 | 37 33.8 29.2 |
| Age Groups               |          |         |             |          |         |             |          |         |             |
| <40                      | 2,807 33.9 26.3 <0.01 | 33 27.8 23.8 <0.01 | 961 9.9 5.8 <0.01 | 7.1 6 6.1 <0.01 | 546 4.8 2.3 <0.01 | 3 2.1 2.7 <0.01 |
| 41–65                    | 4,681 51.6 45.6 | 50.5 48.5 42.2 | 5,974 52.4 37.7 | 46.6 38.6 34.6 | 8,200 50.9 37.3 | 42.3 38.6 35 |
| >65                      | 2,426 14.5 28.1 | 16.5 23.6 34 | 8,077 37.7 56.5 | 46.4 55.5 59.3 | 12,315 44.3 60.4 | 54.7 59.3 62.3 |
| Unknown                  | 261 119 | 88 |
| Race                     |          |         |             |          |         |             |          |         |             |
| Caucasian                | 8,043 72.3 82.4 <0.01 | 77.2 77.7 84.7 <0.01 | 14,015 89.7 93.6 <0.01 | 93.8 92.8 92.6 0.11 | 19,266 89.7 92.5 <0.01 | 90.5 92.7 91.7 <0.01 |
| AA                       | 1,911 26.6 16.1 | 21.8 20.5 14.1 | 935 9.5 5.8 | 5.7 6.5 6.8 | 1,632 14.4 6.9 | 8.9 6.6 7.7 |
| Other                    | 138 1.1 1.4 | 1.1 1.8 1.2 | 89 0.8 0.6 | 0.5 0.7 0.6 | 133 0.6 0.6 | 0.6 0.6 0.6 |
| Unknown                  | 83 74 | 118 |
| Ethnicity                |          |         |             |          |         |             |          |         |             |
| Hispanic                 | 1,315 21 10.2 <0.01 | 18.3 12.3 8.4 <0.01 | 1,164 13.7 6.8 <0.01 | 8.6 6.5 8.2 <0.01 | 1,769 16 7.5 <0.01 | 12.8 2.6 9.9 <0.01 |
| Non-Hispanic             | 8,711 79 89.8 | 81.7 87.7 91.6 | 13,788 86.3 93.2 | 91.4 93.5 91.8 | 19,077 84 92.5 | 87.2 97.4 90.1 |
| Unknown                  | 149 179 | 303 |
| Primary Payor            |          |         |             |          |         |             |          |         |             |
| insured                  | 2,682 38.5 52.4 <0.01 | 42.2 56.2 47.1 <0.01 | 3,531 42.4 40.6 <0.01 | 46 38.6 38.3 <0.01 | 4,677 38.7 39.8 <0.01 | 42.5 37 39 <0.01 |
| non-insured              | 780 24.3 10.6 | 21.6 12.4 9 | 335 6.8 3.4 | 4.4 3.6 3.7 | 438 10.7 2.7 | 5.4 2.6 2.8 |
| Medicare                 | 474 4.5 10 | 5.4 8.8 11.5 | 1,884 15.3 22.9 | 23.3 25.6 17.4 | 2,645 16.2 23.3 | 24.8 26.8 15.1 |
| Medicaid                 | 721 21.4 10.2 | 19 10.9 9.8 | 309 8.7 2.7 | 4.6 3.3 3 | 322 7.4 2.1 | 2.7 2.8 2.7 |
| Medicare/Medicaid NOS    | 825 10.8 16.5 | 11.4 11.2 22.4 | 2,568 26.8 30.2 | 21.6 28.8 37.5 | 3,705 26.6 32.1 | 24.3 30.7 40.3 |
| Government               | 19 10.8 16.5 | 0.4 0.5 0.2 | 11 0.1 0.1 | 0.3 0.1 0.1 | 17 0.4 0.1 | 0.2 0.1 0.1 |
| Unknown                  | 4,674 | 6,493 | 9,345 |
| LN examined              |          |         |             |          |         |             |          |         |             |
| none                     | 3,277 26.1 34.4 <0.01 | 22.9 33.4 40.9 <0.01 | 5,229 31.9 35 <0.01 | 29 35.8 38.6 <0.01 | 7,063 28.5 34.1 <0.01 | 26.6 34.5 40.7 <0.01 |
| 1 through 10             | 510 5.1 5 | 6.2 6 2.6 | 1,165 11.3 7.1 | 11 7.6 4.8 | 2,308 14 10.5 | 13.5 11.5 6.9 |
| 11 through 20            | 671 8.1 6 | 10.4 6.8 2.3 | 423 4.1 2.6 | 5.2 2.1 1.2 | 1,128 8.4 4.9 | 8.9 42.1 |
| 21–30                    | 537 7.8 4.4 | 9.5 4.7 1.3 | 219 1.6 1.4 | 2.8 1.4 0.2 | 656 3.5 3 | 5.6 23.9 |
| >30                      | 410 7.3 28 | 6.4 4.4 1 | 66 0.7 0.4 | 0.8 0.5 0.1 | 280 2.1 1.2 | 2.4 1 0.4 |
| unknown                  | 4,770 | 8,029 | 9,717 |
### Table 1. cont.

| Tumor stage | Cervical Facility Hospital Volume | Ovarian Facility Hospital Volume | Endometrial Facility Hospital Volume |
|-------------|----------------------------------|----------------------------------|-------------------------------------|
|             | TF NTF p | HVC IVC LVC p^ | TF NTF p | HVC IVC LVC p | TF NTF p | HVC IVC LVC p |
| Localized   | 4.66 3  | 51.5 55.2 <0.01 54.1 52.3 56.5 <0.01 | 2.45 1 73.1 19.6 <0.01 19.2 18 20.5 <0.01 | 13.84 9 69.1 76.7 <0.01 73 76.6 78.9 <0.01 |
| Regional    | 2.99 3  | 37.5 33.6 <0.01 34.7 37.5 30.8 <0.01 | 1.49 1 9.2 12.2 <0.01 11.9 13.4 10 <0.01 | 2.70 5 17.8 14.4 <0.01 16.4 149 12.3 |
| Distant     | 0.93 1  | 11 11.2 <0.01 11.2 10.1 12.6 <0.01 | 8.77 1 37.5 68.2 <0.01 68.9 68.6 69.5 <0.01 | 1.72 2 13.1 8.9 | 10.6 8.5 8.8 |
| Unknown     | 1.55 6  | 4.1 4.1 <0.01 4.1 4.1 4.1 <0.01 | 2.41 4 2.41 2.41 2.41 <0.01 | 2.87 3 2.87 2.87 2.87 <0.01 |

| Tumor Grade | Cervical Facility Hospital Volume | Ovarian Facility Hospital Volume | Endometrial Facility Hospital Volume |
|-------------|----------------------------------|----------------------------------|-------------------------------------|
|             | TF NTF p | HVC IVC LVC p | TF NTF p | HVC IVC LVC p | TF NTF p | HVC IVC LVC p |
| Well differentiated | 8.1 0 7.2 8.3 <0.01 7.7 7.3 9.1 <0.01 | 1.06 1 7.6 6.9 <0.01 8.4 6 6.6 <0.01 | 7.47 1 31.8 35.8 <0.01 33.6 36.6 36.2 <0.01 |
| Moderately differentiated | 2.47 3 24.5 24.2 <0.01 25.5 23.5 23.9 <0.01 | 2.08 7 15.5 14.4 | 16.4 13.4 14 <0.01 | 6.24 8 28.3 29.7 <0.01 28.6 30.4 29.8 |
| Poorly differentiated | 2.54 6 29.5 23.4 <0.01 29.1 24.7 21 <0.01 | 4.74 1 34.7 29.5 <0.01 35.2 32.4 23.6 <0.01 | 3.59 0 19.9 16.6 <0.01 19.1 17.1 14.2 |
| Undifferentiated | 0.17 1 1.4 1.9 <0.01 1.7 1.8 1.7 <0.01 | 0.56 1 4.5 3.6 <0.01 3.9 4.1 3.3 <0.01 | 0.41 1 3.2 1.8 | 2.6 1.6 1.5 |
| Unknown     | 4.16 9  | 4.16 9 <0.01 4.16 9 <0.01 | 6.42 1 6.42 1 <0.01 | 3.42 3 3.42 3 <0.01 |

| Surgical Extirpation | Cervical Facility Hospital Volume | Ovarian Facility Hospital Volume | Endometrial Facility Hospital Volume |
|----------------------|----------------------------------|----------------------------------|-------------------------------------|
| Yes                  | 6.16 1 62.6 59.9 0.02 68 57.4 56.9 <0.01 | 11.69 4 15.3 23.8 <0.01 82.9 78.7 71.1 <0.01 | 17.99 3 89.2 84.6 <0.01 89 87.4 77.5 <0.01 |
| No                   | 3.99 7 37.4 40.1 <0.01 32 42.6 43.1 <0.01 | 3.41 3 15.3 23.8 <0.01 17.1 21.3 28.9 <0.01 | 3.14 2 10.8 15.4 <0.01 11 12.6 22.5 |
| Unknown              | 0.17 1 24 <0.01 | 24 <0.01 | 24 <0.01 | 14 <0.01 |

| Chemotherapy | Cervical Facility Hospital Volume | Ovarian Facility Hospital Volume | Endometrial Facility Hospital Volume |
|--------------|----------------------------------|----------------------------------|-------------------------------------|
| Yes          | 1.42 9 16.1 13.6 <0.01 18.2 13.9 10.3 <0.01 | 7.58 3 63.4 50 <0.01 61.2 56.4 38.4 <0.01 | 1.01 4 7.9 4.5 <0.01 7.1 4.3 2.6 <0.01 |
| No           | 8.59 4 83.9 86.4 <0.01 81.8 86.1 89.7 <0.01 | 7.01 4 36.6 50 <0.01 38.8 43.6 61.6 <0.01 | 19.82 0 92.1 95.5 <0.01 92.9 95.7 97.4 |
| Unknown      | 0.15 2 524 <0.01 | 524 <0.01 | 524 <0.01 | 315 <0.01 |

| Radiation | Cervical Facility Hospital Volume | Ovarian Facility Hospital Volume | Endometrial Facility Hospital Volume |
|-----------|----------------------------------|----------------------------------|-------------------------------------|
| Yes       | 4.42 3 45.5 43.6 0.09 42.6 53 35.4 <0.01 | 45.1 2 26 3.1 0.25 3.3 3.7 2.1 <0.01 | 4.52 3 21.5 21.8 0.67 25.9 26 11.4 <0.01 |
| No        | 5.39 7 54.5 56.4 <0.01 57.4 47 64.6 <0.01 | 14.30 4 97.4 96.9 | 96.7 96.3 97.9 <0.01 | 16.22 1 78.5 78.2 <0.01 | 74.1 1 74 88.6 |
| Unknown   | 0.15 2 177 <0.01 | 177 <0.01 | 177 <0.01 | 405 <0.01 |

| Uterine Sarcoma | Cervical Facility Hospital Volume | Vulvar Facility Hospital Volume |
|----------------|----------------------------------|--------------------------------|
| Median age at diagnosis (years) | TF NTF p | HVC IVC LVC p |
| Overall     | 60 61.3 60 0.77 54.8 58.4 66.4 <0.01 | 67.6 63 69.2 <0.01 64.1 68 71 <0.01 |
| n % of total | n % of total | n % of total |
| Overall     | 253 19.4 80.6 39.9 34.8 25.3 | 2.27 3 25.7 74.3 | 34.1 34.4 31.5 |

| Age Groups | Cervical Facility Hospital Volume | Vulvar Facility Hospital Volume |
|------------|----------------------------------|--------------------------------|
| <40        | 25 13 9.5 0.67 11.6 12.5 4.8 0.04 | 199 12.3 7.5 <0.01 11.2 7.5 7.4 <0.01 |
| 41–65      | 141 58.7 57 61.1 60.2 47.6 | 675 37 27.2 | 35.3 28.1 25.4 |
Table 1. cont

| Uterine Sarcoma | Vulvar       |
|-----------------|--------------|
| Overall Facility | Hospital Volume | Overall Facility | Hospital Volume |
| TF   | NTF | p<sup>a</sup> | TF   | NTF | p<sup>a</sup> | HVC | IVC | LVC | p<sup>a</sup> | TF   | NTF | p<sup>a</sup> | HVC | IVC | LVC | p<sup>a</sup> |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| >65 | 80  | 28.3 | 33.5 | 27.4 | 27.3 | 47.6 | 1,399 | 50.7 | 65.3 | 53.5 | 64.3 | 67.2 |
| Unknown | 7   | 0    |      |      |      |      |      |      |      |      |      |      |      |      |
| Race |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| Caucasian | 209 | 69.4 | 86.6 | 0.01 | 81 | 83.9 | 85.9 | 0.63 | 2,120 | 90.4 | 94.3 | 0.01 | 91.2 | 94.5 | 94.1 | 0.05 |
| AA | 38  | 26.5 | 12.4 | 16 | 14.9 | 14.1 | 125 | 7.7 | 4.7 | 7.5 | 4.5 | 4.5 |
| Other | 4   | 4.1 | 1 | 3 | 1.1 | 0 | 28 | 1.9 | 1 | 1.3 | 1 | 1.4 |
| Unknown | 2   | 0    |      |      |      |      |      |      |      |      |      |      |      |
| Ethnicity |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| Hispanic | 30  | 14.3 | 11.5 | 0.63 | 17.2 | 9.3 | 7.8 | 0.13 | 139 | 7.6 | 5.7 | 0.11 | 64 | 8.6 | 3.4 | <0.01 |
| Non-Hispanic | 219 | 85.7 | 88.5 | 82.8 | 90.7 | 92.2 | 2,106 | 92.4 | 94.3 | 93.6 | 91.4 | 96.6 |
| Unknown | 4   | 8    |      |      |      |      |      |      |      |      |      |      |      |
| Primary Payor |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| insured | 82  | 40 | 57.6 | <0.01 | 50 | 57.4 | 54.3 | 0.14 | 511 | 34.3 | 38 | <0.01 | 31.8 | 42.5 | 36.6 | <0.01 |
| non-insured | 14  | 17.1 | 6.8 | 7.8 | 9.3 | 11.4 | 59 | 10 | 2.5 | 8.1 | 2.8 | 1.7 |
| Medicare | 20  | 11.4 | 13.6 | 21.9 | 9.3 | 2.9 | 333 | 14.3 | 27.3 | 25.2 | 26.2 | 20.4 |
| Medicaid | 9   | 20.1 | 1.7 | 4.7 | 9.3 | 2.9 | 74 | 10.3 | 3.8 | 9.1 | 2.6 | 4.5 |
| Medicare/Medicaid NOS | 28  | 11.4 | 20.3 | 15.6 | 14.8 | 28.6 | 400 | 31 | 28.4 | 25.8 | 25.8 | 36.8 |
| Government | 0   | 0    | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 100 | 896  |      |      |      |      |      |      |      |      |      |      |
| LN examined |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| none | 102 | 36.7 | 41.2 | 0.39 | 35.6 | 44.3 | 42.2 | <0.01 | 759 | 28.4 | 35.1 | <0.01 | 25.6 | 32.9 | 42.4 | <0.01 |
| 1 through 10 | 25  | 16.3 | 8.3 | 13.9 | 10.2 | 3.1 | 244 | 8.4 | 11.5 | 11.9 | 13.8 | 6.1 |
| 11 through 20 | 16  | 6.1 | 6.4 | 12.9 | 3.4 | 0 | 255 | 16.1 | 9.5 | 19.6 | 10.5 | 2.9 |
| 21–30 | 5   | 0 | 2.5 | 4 | 1.1 | 0 | 94 | 5.1 | 3.8 | 7.5 | 3.5 | 1.3 |
| >30 | 2   | 2 | 0.5 | 0 | 2.3 | 0 | 28 | 2.9 | 0.7 | 2.5 | 1.2 | 0 |
| unknown | 103 | 893  |      |      |      |      |      |      |      |      |      |      |
| Tumor stage |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| Localized | 131 | 47.5 | 61.5 | 0.24 | 56 | 59.5 | 63.5 | 0.77 | 1,422 | 68.6 | 72.7 | 0.19 | 67 | 73.3 | 75.5 | <0.01 |
| Regional | 40  | 25 | 16.5 | 19.8 | 15.2 | 19.2 | 476 | 26.6 | 23 | 27.9 | 23.3 | 19.7 |
| Distant | 51  | 27.5 | 22 | 24.2 | 25.3 | 17.3 | 88 | 4.8 | 4.3 | 5.1 | 3.4 | 4.8 |
| Unknown | 41  | 287  |      |      |      |      |      |      |      |      |      |      |
| Tumor Grade |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| Well differentiated | 67  | 16.3 | 28.9 | <0.01 | 28.7 | 27.3 | 21.9 | 0.23 | 426 | 36.7 | 34.4 | 0.69 | 34.3 | 34.6 | 36.5 | 0.5 |
Table 1. cont.

| Uterine Sarcoma | Vulvar |
|-----------------|--------|
| Facility overall | Facility overall |
| TF | NTF | HVC | IVC | LVC | TF | NTF | HVC | IVC | LVC |
| Moderately differentiated | 38 | 8.2 | 16.7 | 15.8 | 14.8 | 14.1 | 529 | 1.2 | 44.3 | 44.1 | 43.4 | 42.6 |
| Poorly differentiated | 25 | 14.3 | 8.8 | 12.9 | 8 | 7.8 | 247 | 21.2 | 20 | 21.1 | 20.1 | 19.4 |
| Undifferentiated | 41 | 32.7 | 12.3 | 19.8 | 15.9 | 10.9 | 15 | 0.9 | 1.4 | 0.4 | 2 | 1.5 |
| Unknown | 82 | 28.6 | 33.3 | 22.8 | 34.1 | 45.3 | 1,056 |

Surgical Extirpation

| | Yes | No | Unknown |
| TF | NTF | HVC | IVC | LVC | TF | NTF | HVC | IVC | LVC |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Moderately differentiated | 213 | 87.8 | 83.3 | 0.52 | 90.1 | 83 | 76.6 | 0.06 | 2,012 | 91.8 | 87.4 | <0.01 | 92.8 | 91 | 81.3 | <0.01 |
| Poorly differentiated | 40 | 12.2 | 16.7 | 9.9 | 17 | 23.4 | 260 | 8.2 | 12.6 | 7.2 | 9 | 18.7 |
| Undifferentiated | 0 | 1 |

Chemotherapy

| | Yes | No |
| TF | NTF | HVC | IVC | LVC | TF | NTF | HVC | IVC | LVC |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Moderately differentiated | 27 | 16.7 | 9.5 | 0.19 | 16 | 10.5 | 3.2 | 0.04 | 89 | 3.6 | 4.1 | 0.71 | 4.4 | 4.3 | 3.1 | 0.39 |
| Poorly differentiated | 221 | 83.3 | 90.5 | 84 | 89.5 | 96.8 | 2,161 | 96.4 | 95.9 | 95.6 | 95.7 | 96.9 |
| Undifferentiated | 5 |

Radiation

| | Yes | No |
| TF | NTF | HVC | IVC | LVC | TF | NTF | HVC | IVC | LVC |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Moderately differentiated | 46 | 20.4 | 18.1 | 0.69 | 19.8 | 23.5 | 9.7 | 0.09 | 294 | 11.2 | 13.8 | 0.12 | 12.7 | 13.6 | 13 | 0.88 |
| Poorly differentiated | 202 | 79.6 | 81.9 | 80.2 | 76.5 | 90.3 | 1,948 | 88.8 | 86.2 | 87.3 | 86.4 | 87 |
| Undifferentiated | 5 | 23 |

TF = teaching facility; NTF = non-teaching facility; HVC = high-volume center; IVC = intermediate volume center; LVC = low volume center; AA = African American.

\( p^a \) value = chi square analysis of survival at TF vs NTF.

\( p^b \) value = chi square analysis of survival at HVC vs. IVC vs. LVC.

doi:10.1371/journal.pone.0004049.t001
demonstrated a dose-response relationship, with further risk reduction when more nodes were examined. Patients with gynecological cancer were 2.08 times more likely to die when they had regionally advanced disease (HR = 2.08, p < 0.01) and 3.92 times more likely to die when they had distant staged disease (HR = 3.92, p < 0.01) compared to patients with localized cancer.

More poorly differentiated gynecological cancers portended a worse prognosis, as an increased risk of death in the 10-year study period was observed in patients with moderately and poorly differentiated malignancies compared to patients with well-differentiated tumors. Patients with a gynecologic malignancy were at a 57% increased risk of death (HR = 1.57, p < 0.01) if they were not treated surgically, compared to patients who were treated surgically for their cancers. Those patients who did not receive chemotherapy treatment were at an 8% increased risk of death (HR = 1.08, p < 0.01) compared to patients who were treated with chemotherapy. Patients who did not receive radiation therapy for their gynecologic malignancy had a 10% decreased risk of death (HR = 0.90, p < 0.01) compared to those patients who were treated with radiation therapy. Stepwise regression models evaluating the impact of patient characteristics, tumor characteristics, and treatment for each individual cancer type did not alter the significance of results (data not shown).

Discussion

It has been demonstrated that the median survival and cure rates for patients diagnosed with certain malignancies, such as sarcomas of the trunk and retroperitoneum and cancers arising in the esophagus and pancreas, are improved when treatment is provided in specialized centers such as high-volume centers (HVC) and teaching facilities (TF). This has not been fully comprehensively determined for the field of gynecologic malignancies. To our knowledge this represents the first, and largest, study providing an overview of the entire field of gynecological malignancies and the effects of hospital volume and teaching status to date.

The five malignancies studied represent >98% of all gynecologic malignancies reported to the FCDS database. Multiple Cox regression analyses were modeled in order to identify any differences that may have gone undetected. These models included analysis in which each individual cancer was analyzed - cervical, endometrial, and ovarian - and one final model in which all patients with a gynecological malignancy were included. Patients with uterine sarcomas and vulvar cancers were excluded from the individual Cox regression modeling because multivariate analysis of these cancers resulted in no significant predictors of survival for any of the demographic, clinical or treatment variables. We suspect inadequate sample size for these specific cancers as the explanation for these observations.

Overall for all five gynecologic malignancies, and separately for cervical, endometrial, and ovarian cancer, no demonstrable benefit for either high volume center or teaching status on patient survival was observed. We did not have complete data on treating physician specialty, making it difficult to determine what these results mean in terms of specific providers. Of note, we were able to determine that all high volume facilities and teaching hospitals examined in this study had board-certified gynecologic oncologists on staff. Many of the low volume centers did not have board-certified gynecologic oncologists on staff, which suggests that other medical professionals, likely general obstetrician-gynecologists or general surgeons, may have delivered care.

There are several possible explanations as to why we fail to find survival benefits at TFs or HVCs. Gynecologic oncology fellowship training may be well standardized and patients treated by these specialists at NTFs or LVCs are provided equivalent care. In addition, gynecological surgeries - i.e. hysterectomies - are performed for a number of reasons other than for malignancies. General obstetrician-gynecologists and general surgeons are often the providers performing the surgical extirpation for benign reasons. As such, these providers may get the necessary case volume to become proficient with these procedures. Thus, while certain subsets of patients may benefit from treatment by gynecologic oncologists, we did not find evidence for a significant survival advantage for patients when they were treated at TFs or HVCs.

Many studies in ovarian cancer have focused on provider specialty type (general gynecologist versus gynecologic oncologist), rather than volumes, specifically. Several studies have found that treatment at specialized hospitals including high-volume centers with gynecologic oncologists as providers, are more likely to include staging procedures, lymph node biopsy, “optimal” debulking and chemotherapy according to guidelines compared to non-specialized hospitals.[2,3,4,5,6,8,9,13] Many of these studies were limited by the use of Medicare-linked Surveillance, Epidemiology, and End Results (SEER) data, which includes only patients older than 65 years, a variable we have demonstrated is an independent predictor of worse survival outcomes. Of note, Woodman et al found no survival advantage for ovarian cancer patients treated by high-volume operators compared to low volume-operators; however, they had many fewer cases to analyze than in our cohort.[10]

In simple regression analysis models, common in many outcome studies currently in the literature, independence of each individual patient is assumed. However, outcome studies in which hospital volume or teaching status is examined, patients treated within the same facility are not entirely independent. Outcomes of patients treated at one facility tend to be more similar to one another than the outcomes of patients treated at an entirely different facility, a concept known as clustering.[30] As such, studies that do not account for clustering may exaggerate the statistical significance of differences in outcome by provider.[24,30]

None of the ovarian cancer volumes studies we could identify in the literature, to date, have accounted for this particular phenomenon. Initially, without correction for clustering, a significant improvement for patients with ovarian cancer treated at teaching facilities was observed in our dataset. We found patients treated at a LVC had an 18% increased risk of death (HR = 1.18, p < 0.001). Previous studies on ovarian cancer regionalization have made similar observations. These studies, however, have not included corrections for the clustering phenomenon.[1,2,3,4,6,7,8,9,10] After re-analysis, accounting for clustering in our dataset, we no longer find a survival benefit for ovarian cancer patients treated at high-volume centers. This suggests that corrections for clustering is crucial in these types of
### Table 2. Surgical Mortality and 5-Year Survival of the Study Group.

|                      | Cervical | Ovarian | Endometrial |
|----------------------|----------|---------|-------------|
|                      | Facility | Hospital Volume | Facility | Hospital Volume | Facility | Hospital Volume |
|                      | Overall | TF | NTF | p<sup>a</sup> | Overall | TF | NTF | p<sup>b</sup> | Overall | TF | NTF | p<sup>c</sup> |
| Surgical Mortality (%) |         |     |     |            |         |     |     |            |         |     |     |            |
| 30 day               | 1.5     | 0.8 | 0.47 | 0.01 | 1.3     | 0.64 | 0.38 | 0.01 | 2.0     | 0.89 | 0.42 | 0.01 |
| 90 day               | 3.7     | 2.4 | 0.67 | 0.01 | 2.9     | 3.5  | 1.18 | 0.01 | 7.2     | 3.5  | 4.3  | 0.54 |
| 5 year Survival (Proportion Surviving %) |         |     |     | 0.01 |         |     |     | 0.01 |         |     |     | 0.01 |
| Overall              | 61.7    | 63.9 | 60.9 | 0.00 | 55.4    | 60.3 | 59.5 | 0.00 | 56.0    | 61.1 | 57.4 | 0.00 |
| Age Groups           |         |     |     |      |         |     |     |      |         |     |     |      |
| <40                  | 76.0    | 74.6 | 75.6 | 0.02 | 75.6    | 74.3 | 78.0 | 0.01 | 76.6    | 73.4 | 77.6 | 0.01 |
| 41–65                | 63.1    | 62.4 | 62.4 | 0.05 | 60.7    | 62.9 | 65.0 | 0.00 | 60.7    | 63.6 | 67.3 | 0.01 |
| >65                  | 41.4    | 45.7 | 40.6 | 0.00 | 46.5    | 40.8 | 39.3 | 0.01 | 32.4    | 28.5 | 25.6 | 0.00 |
| Race                 |         |     |     |      |         |     |     |      |         |     |     |      |
| Caucasian            | 63.2    | 64.6 | 62.7 | 0.03 | 60.6    | 62.4 | 61.2 | 0.01 | 44.7    | 38.9 | 36.5 | 0.01 |
| AA                   | 54.2    | 41.7 | 49.8 | 0.01 | 56.9    | 55.7 | 47.3 | 0.01 | 33.7    | 29.1 | 27.8 | 0.01 |
| Other                | 67.5    | 59.3 | 69.9 | 0.01 | 58.2    | 72.2 | 68.6 | 0.03 | 57.1    | 56.3 | 57.3 | 0.03 |
| Ethnicity            |         |     |     |      |         |     |     |      |         |     |     |      |
| Hispanic             | 66.4    | 65.3 | 67.2 | 0.33 | 66.8    | 67.9 | 63.1 | 0.18 | 42.2    | 40.7 | 40.1 | 0.07 |
| Non-Hispanic         | 60.9    | 62.9 | 60.0 | 0.00 | 63.4    | 60.3 | 59.2 | 0.00 | 36.8    | 41.8 | 40.3 | 0.00 |
| Primary Payor         |         |     |     |      |         |     |     |      |         |     |     |      |
| insured              | 71.6    | 71.6 | 71.6 | 0.58 | 71.1    | 71.7 | 72.0 | 0.02 | 47.8    | 33.7 | 47.4 | 44.4 |
| non-insured          | 63.1    | 64.6 | 61.9 | 0.60 | 65.1    | 64.7 | 56.2 | 0.10 | 53.5    | 46.0 | 40.6 | 0.01 |
| Medicare             | 52.0    | 59.7 | 50.7 | 0.10 | 59.8    | 53.5 | 47.1 | 0.08 | 37.8    | 44.6 | 37.0 | 0.00 |
| Medicaid             | 59.4    | 60.6 | 58.4 | 0.04 | 59.3    | 62.7 | 55.4 | 0.24 | 43.4    | 40.1 | 45.1 | 42.6 |
| Medicare/Medicaid NOS| 45.1    | 52.3 | 45.5 | 0.05 | 52.4    | 42.2 | 48.1 | 0.04 | 31.2    | 35.3 | 30.6 | 0.00 |
| Government           | 74.2    | 70.0 | 58.9 | 0.01 | 58.0    | 65.0 | 50.0 | 0.36 | 70.0    | 77.8 | 64.6 | 0.00 |
| LN examined          |         |     |     |      |         |     |     |      |         |     |     |      |
| none                 | 55.9    | 55.6 | 56.0 | 0.37 | 51.7    | 56.1 | 58.2 | 0.01 | 31.8    | 37.1 | 31.0 | 0.01 |
| 1 through 10         | 65.8    | 63.6 | 66.6 | 0.24 | 60.9    | 68.4 | 71.6 | 0.05 | 53.7    | 52.8 | 54.0 | 0.08 |
| 11 through 20        | 77.4    | 74.6 | 78.8 | 0.19 | 76.9    | 77.9 | 78.2 | 0.07 | 60.7    | 58.5 | 61.3 | 0.57 |
| 21–30                | 80.7    | 74.9 | 84.5 | 0.00 | 81.2    | 80.6 | 77.1 | 0.02 | 68.4    | 78.8 | 66.3 | 0.16 |
| >30                  | 82.0    | 83.1 | 81.0 | 0.02 | 84.9    | 75.5 | 93.4 | 0.05 | 57.4    | 63.0 | 55.8 | 0.31 |
| Unknown              | 59.5    | 62.1 | 58.6 | 0.01 | 40.6    | 43.8 | 40.1 | 0.00 | 37.5    | 43.0 | 37.5 | 0.00 |
| Tumor stage          |         |     |     |      |         |     |     |      |         |     |     |      |
| Localized            | 81.0    | 82.7 | 80.4 | 0.04 | 83.0    | 80.4 | 79.3 | 0.02 | 78.6    | 81.3 | 78.1 | 0.10 |
| Regional             | 48.6    | 51.2 | 47.4 | 0.02 | 50.5    | 48.8 | 45.2 | 0.01 | 48.9    | 64.0 | 46.9 | 0.01 |
Table 2. cont.

|                      | Cervical | Ovarian | Endometrial |
|----------------------|----------|---------|-------------|
|                      | Overall $p^a$ | Facility | Hospital Volume | Overall $p^a$ | Facility | Hospital Volume | Overall $p^a$ | Facility | Hospital Volume |
|                      | TF  | NTF | $p^b$ | HVC | IVC | LVC | TF  | NTF | $p^b$ | HVC | IVC | LVC | TF  | NTF | $p^b$ | HVC | IVC | LVC |
| Distant              | 19.5 | 24.4 | 17.6 | 0.00 | 23.0 | 17.4 | 17.6 | <0.01 | 25.8 | 31.6 | 24.7 | <0.01 | 27.8 | 28.0 | 22.0 | <0.01 | 20.3 | 19.1 | 20.6 | 0.52 | 17.3 | 23.2 | 22.1 | 0.01 |
| Tumor Grade          |        |        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Well differentiated   | 74.5  | <0.01 | 74.7 | 74.4 | 0.85 | 76.1 | 72.5 | 74.9 | 0.79 | 68.4  | <0.01 | 64.7 | 69.0 | 0.68 | 71.0 | 67.7 | 65.7 | 0.10 | 83.0  | <0.01 | 83.1 | 83.0 | 0.55 | 82.4 | 83.9 | 82.5 | 0.25 |
| Moderately differentiated | 62.6 | 6.6  | 61.3 | 0.02 | 65.6 | 62.0 | 59.8 | 0.02 | 44.7  | 48.5 | 44.0 | 0.08 | 44.8 | 46.7 | 42.7 | 0.10 | 71.5  | 69.0 | 71.8 | 0.26 | 71.8 | 73.2 | 69.2 | 0.01 |
| Poorly differentiated | 54.3  | 59.8 | 51.9 | <0.01 | 60.7 | 52.9 | 46.9 | <0.01 | 31.9  | 34.9 | 31.3 | 0.00 | 33.6 | 33.8 | 27.2 | <0.01 | 44.4  | 47.6 | 43.9 | 0.14 | 44.7 | 45.0 | 43.1 | 0.18 |
| Undifferentiated     | 40.5  | 38.9 | 41.0 | 0.63 | 55.0 | 32.8 | 34.6 | 0.05 | 32.2  | 39.5 | 30.7 | 0.23 | 31.4 | 36.9 | 27.6 | 0.01 | 30.4  | 30.3 | 30.5 | 0.61 | 25.8 | 38.2 | 30.8 | 0.10 |
| Surgical Exirpation  |        |        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Yes                  | 75.0  | <0.01 | 76.5 | 74.4 | 0.04 | 76.5 | 75.4 | 72.5 | <0.01 | 45.7  | <0.01 | 47.2 | 45.4 | 0.07 | 46.3 | 46.6 | 44.1 | <0.01 | 70.8  | <0.01 | 68.6 | 71.1 | 0.08 | 69.4 | 72.4 | 70.6 | <0.01 |
| No                   | 41.7  | 43.2 | 41.2 | 0.03 | 38.5 | 42.9 | 42.9 | 0.03 | 18.9  | 26.3 | 18.2 | <0.01 | 22.8 | 18.0 | 17.4 | <0.01 | 48.0  | 40.2 | 48.8 | 0.13 | 39.3 | 45.2 | 55.4 | <0.01 |
| Chemotherapy         |        |        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Yes                  | 40.5  | <0.01 | 41.0 | 40.4 | 0.68 | 43.7 | 38.6 | 37.4 | 0.49 | 37.8  | <0.01 | 42.9 | 36.6 | <0.01 | 40.6 | 38.0 | 32.9 | 0.01 | 30.9  | <0.01 | 33.9 | 30.2 | 0.43 | 31.4 | 29.2 | 32.7 | 0.74 |
| No                   | 65.0  | 68.3 | 63.9 | <0.01 | 68.5 | 64.7 | 62.0 | <0.01 | 41.1  | 45.5 | 40.6 | <0.01 | 44.6 | 42.8 | 37.9 | <0.01 | 69.3  | 68.2 | 69.5 | 0.68 | 68.6 | 70.9 | 68.4 | <0.01 |
| Radiation            |        |        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Yes                  | 47.0  | <0.01 | 50.5 | 45.7 | <0.01 | 47.4 | 48.1 | 44.6 | 0.01 | 40.7  | 0.29 | 43.1 | 40.4 | 0.74 | 43.1 | 41.5 | 35.8 | 0.28 | 60.1  | <0.01 | 61.8 | 59.9 | 0.21 | 59.5 | 61.8 | 57.2 | 0.02 |
| No                   | 73.4  | 75.1 | 72.9 | 0.04 | 76.4 | 76.5 | 68.0 | <0.01 | 39.4  | 44.0 | 38.6 | <0.01 | 42.1 | 40.2 | 36.1 | <0.01 | 69.5  | 66.5 | 69.9 | 0.04 | 68.3 | 71.6 | 68.7 | <0.01 |

TF = teaching facility; NTF = non-teaching facility; HVC = high volume center; IVC = intermediate volume center; LVC = low volume center; AA = African American; ND = not determined.

$\text{pa}^\text{value} = \text{log rank analysis of survival between categorical variables.}$

$\text{pb}^\text{value} = \text{log rank analysis of survival at TF vs NTF.}$

$\text{pc}^\text{value} = \text{log rank analysis of survival at HVC vs. IVC vs. LVC.}$

doi:10.1371/journal.pone.0004049.t002
Table 3. Cox Regression Model for Risk of Death.

| Cancer               | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| Cervical             | 1.13   | 1.07 - 1.20 | <0.01 |
| Ovarian              | 1.52   | 1.43 - 1.63 | <0.01 |
| Endometrial          | 2.61   | 2.41 - 2.83 | <0.01 |
| Uterine sarcoma      | 0.84   | 0.61 - 1.16 | 0.30  |
| Vulvar               | ND     |         |       |

| Hospital Volume      | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| High                 | 0.96   | 0.91 - 1.03 | 0.25  |
| Intermediate+Low     |        |         |       |

| Facility             | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| Teaching             | 1.08   | 0.99 - 1.18 | 0.08  |
| Non-Teaching         |        |         |       |

| Age Groups           | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| <40                  |        |         |       |
| 41–65                | 1.52   | 1.43 - 1.63 | <0.01 |
| >65                  | 2.61   | 2.41 - 2.83 | <0.01 |

| Race                 | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| Caucasian            | 1.36   | 1.27 - 1.45 | <0.01 |
| AA                   | 0.84   | 0.69 - 1.02 | 0.08  |
| Other                |        |         |       |

| Ethnicity            | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| Hispanic             | 0.99   | 0.92 - 1.07 | 0.84  |
| Non-Hispanic         |        |         |       |

| Primary Payor        | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| insured              | 1.00   | 0.91 - 1.11 | 0.98  |
| non-insured          | 1.03   | 0.97 - 1.09 | 0.39  |
| Medicare             | 1.29   | 1.14 - 1.48 | <0.01 |
| Medicaid             | 1.12   | 1.05 - 1.19 | <0.01 |
| Medicare/Medicaid NOS| 0.81   | 0.47 - 1.39 | 0.45  |
| Government           | 1.13   | 1.08 - 1.18 | <0.01 |
| Unknown              |        |         |       |

| Lymph Nodes Examined | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| none examined         | 0.79   | 0.73 - 0.85 | <0.01 |
| 1 to 10              | 0.67   | 0.62 - 0.73 | <0.01 |
| 11 to 20             | 0.62   | 0.55 - 0.70 | <0.01 |
| 20 to 30             | 0.60   | 0.49 - 0.75 | <0.01 |
| >30                  | 0.95   | 0.92 - 0.99 | 0.02  |

| Tumor stage          | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| Localized            | 2.08   | 1.97 - 2.20 | <0.01 |
| Distant              | 3.82   | 3.58 - 4.07 | <0.01 |
| Unknown              | 1.67   | 1.57 - 1.79 | <0.01 |

| Tumor Grade          | HR     | 95% CI | p     |
|----------------------|--------|--------|-------|
| Well differentiated   | 1.47   | 1.38 - 1.57 | <0.01 |
| Moderately differentiated | 1.93   | 1.81 - 2.05 | <0.01 |
| Poorly differentiated | 2.21   | 2.01 - 2.43 | <0.01 |
| Undifferentated       | 1.81   | 1.70 - 1.92 | <0.01 |

Table 3. cont.

| Surgical Exirpation | HR     | 95% CI | p     |
|---------------------|--------|--------|-------|
| Yes                 | 1.57   | 1.52 - 1.64 | <0.01 |
| No                  |        |         |       |

| Chemotherapy        | HR     | 95% CI | p     |
|---------------------|--------|--------|-------|
| Yes                 |        |         |       |
| No                  | 1.08   | 1.03 - 1.13 | <0.01 |

| Radiation           | HR     | 95% CI | p     |
|---------------------|--------|--------|-------|
| Yes                 | 0.90   | 0.86 - 0.94 | <0.01 |
| No                  |        |         |       |

AA = African American, HR = hazard ration, ND = not determined.

# Regionalization for GYN-ONC

Previous studies on endometrial cancer support our findings. Hoekstra et al[14] found costs and operative times are increased when general gynecologists participate in the surgical procedure of patients with early stage endometrial cancer, but perioperative outcomes were similar when compared to procedures performed completely by a gynecologic oncologist. In a small tumor registry, Macdonald et al[15] found that disease-free and cause-specific survival were equivalent in patients treated by general gynecologists or gynecologic oncologists for early stage endometrial carcinoma. These studies limited their sample to early stage cancers, while we have demonstrated that independent of stage, treatment at NTFs and LVCs, with presumably fewer gynecologic oncologists, does not confer a survival disadvantage. Based on this data, management of early stage endometrial cancer by a general obstetrician-gynecologist, and perhaps general surgeons, appears reasonable as there is no evidence of better outcomes when treated by a gynecologic oncologist. Diaz-Montes et al[16] found among women ≥80 years of age with endometrial cancer, there was a 62% reduction in the risk of 30-day mortality when they were managed at high-volume hospitals and a 44% reduction in the risk of 30-day mortality when managed by high-volume surgeons. Once again, this study did not account for clustering effects, which may explain our different results.

The FCDS, which currently includes over 2.7 million records, is a population-based registry of all cancer cases diagnosed and treated in the state of Florida, which represents about 6% of the total U.S. population. Although it represents an excellent database for comparative outcomes analysis, it is not without limitations. This includes the lack of information in the registry on household income; however, information on insurance status and race may serve as an adequate proxy for socioeconomic status. Our dataset also did not contain information on co-morbidities; therefore, the data presented reflects overall survival and not cause-specific survival. Others have demonstrated that inclusion of co-morbidities may not significantly affect results. Eisenkop et al[4] studied the impact of subspecialty training in gynecologic oncology on the management of advanced ovarian cancer and reported that the distribution of perioperative morbidity among ovarian cancer patients treated by subspecialists versus general obstetrician-gynecologists was not significantly different between the two studies as accurate interpretation of the data may not be possible without it. As such, the proper interpretation of our dataset indicates that current chemotherapy and surgical therapies provided are equivalent at all facilities regardless of teaching status or volume.
groups. Furthermore, we submit that ambulatory patients with a large number of comorbidities are less likely to travel farther to regionalized centers.[18] Thus, TFs or HVCs may not necessarily have seen sicker patients and the lack of survival advantage seen at these facilities may not be related to the overall health of the patient. Given the fact that we saw no survival advantage in patients receiving regionalized care after controlling for clustering, it is likely that comorbidity data would not have altered our results. Finally, follow-up of patients in the FCDS is passive and it is likely that comorbidity data would not have altered our results.

Studies on cancer treatment in the surgical literature suggest certain cancers should be treated at HVCs or TFs,[5,19,25,26,27,28,29] Such studies have resulted in a number of national initiatives to improve the delivery of cancer care. The American College of Surgeons, through the development of the National Surgical Quality Improvement Program (NSQIP), has demonstrated since 1991 that the systematic collection, analysis and feedback of risk-adjusted surgical data, including that on hospital volumes, leads to improved outcomes. Although we were not able to demonstrate improved survival outcomes for gynecologic malignancies through regionalized care, the NSQIP initiative of measuring hospitals surgical outcomes and identifying deficiencies can be used as a model for gynecologic malignancies as some differences in regionalized care may exist. Further studies on regionalization of care may serve to improve survival outcomes, just as NSQIP has attempted to do for general surgery and its subspecialties.

In conclusion, we noted improved short-term (30-day and 90-day) survival for cervical, ovarian and endometrial cancers treated at HVCs compared to LVCs, but not long-term (overall) survival for patients with gynecologic malignancies treated at HVCs. After adjusting for clustering effects, there is not a long-term survival advantage for gynecologic cancer patients treated at a TFs or HVCs. These findings suggests further regionalization of gynecologic cancer care will not improve overall patient outcomes.

Author Contributions
Conceived and designed the experiments: KB MC MB. Analyzed the data: KB MC RY MB LGK. Contributed reagents/materials/analysis tools: KB MC RY MB. Wrote the paper: KB MC RY MB LGK. Assisted in revisions: MC. Involved with editing manuscript: RY.

Table 4. Cox Regression Model for Risk of Death*.

| Facility | Reference group | Reference group | Reference group | Reference group | Reference group |
|----------|----------------|----------------|----------------|----------------|----------------|
| Hospital Volume |                |                |                |                |                |
| High     | Reference group | Reference group | Reference group | Reference group | Reference group |
| Intermediate | 0.89 0.26 0.98 0.69 | 0.90 0.04 | 1.33 0.37 | 1.95 0.08 |
| Low      | 0.90 0.21 1.01 0.11 | 0.93 0.16 | 1.10 0.19 | 1.23 0.07 |
| Facility |                |                |                |                |                |
| Teaching | Reference group | Reference group | Reference group | Reference group | Reference group |
| Non-Teaching | 1.15 0.23 | 1.09 0.12 | 1.02 0.75 | 1.58 0.08 | 1.12 0.44 |

*regression model includes all covariates - HR shown only for hospital volume and facility type.

doi:10.1371/journal.pone.0004049.t004

References
1. Bristol RE, Zahurak ML, del Carmen MG, Gordon TA, Fox HE, et al. (2004) Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol 93: 353–360.
2. Carney ME, Lancaster JM, Ford G, Tsiodtok A, Wiggins CL, et al. (2002) A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84: 36–42.
3. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, et al. (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98: 172–180.
4. Eisenkop SM, Spirtos NM, Montag C, Wiggins CJ, et al. (2000) Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 18: 2323–2340.
5. Hoekstra A, Singh DK, Garb MB, Aarkopulski A, Kademaker A, et al. (2006) Participation of the general gynecologist in surgical staging of endometrial cancer: analysis of cost and perioperative outcomes. Gynecol Oncol 103: 897–901.
6. Mayer AR, Chambers SK, Graves E, Holm C, Tseng PC, et al. (1992) Ovarian cancer staging does it require a gynecologic oncologist? Gynecol Oncol 47: 223–227.
7. Nguyen BN, Averette HE, Hoskins W, Penalver M, Sevin BU, et al. (1993) National survey of ovarian carcinoma. Part V. The impact of physician’s specialty on patients’ survival. Cancer 72: 3663–3670.
8. Puls LE, Carrasco R, Morrow MS, Blackhurst D (1997) Stage I ovarian carcinoma: specialty-related differences in survival and management. South Med J 90: 1097–1100.
9. Vermooij F, Heintz P, Witteveen E, van der Graaf Y (2007) The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 105: 801–812.
10. Woodman C, Baghdady A, Collins S, Clyma JA (1997) What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol 104: 135–139.
11. Junor EJ, Hele DJ, McNulty L, Mason M, Young J (1999) Specialist gynecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106: 1130–1136.
12. Schrag D, Earle C, Xu F, Panagare KS, Yabroff KR, et al. (2006) Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst 98: 163–171.
13. Silver JL, Rosenbaum PR, Polsky D, Ross RN, Even-Shoshan O, et al. (2007) Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol 25: 1169–1175.
14. Macdonald OK, Sause WT, Lee RJ, Doxon MK, Zempolich K, et al. (2005) Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium? Gynecol Oncol 99: 730–735.
15. Diaz-Montes TP, Zahurak ML, Giuntoli RL, 2nd, Bristow RE (2007) Concentration of uterine cancer surgical care among the elderly: a population-based perspective. Gynecol Oncol 107: 436–440.
16. Diaz-Montes TP, Zahurak ML, Giuntoli RL, 2nd, Gardner GJ, Bristow RE (2006) Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality. Gynecol Oncol 103: 1043–1047.
17. Cheung MC, Hamilton K, Sherman R, Byrne MM, Nguyen DM, et al. (2008) Impact of Teaching Facility Status and High-Volume Centers on Outcomes for
Lung Cancer Resection: An Examination of 13,469 Surgical Patients. Ann Surg Oncol.

19. Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, et al. (2007) Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg 245: 852–858.

20. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D (2005) Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 19: 1610–1612.

21. Perez EA, Koniaris LG, Snell SE, Gutierrez JC, Sumner WE 3rd, et al. (2007) 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 31: 1022–1030.

22. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, et al. (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202: 623–629.

23. Molina MA, Cheung MC, Perez EA, Byrne MM, Franceschi D, et al. (2008) African American and Poor Patients Have a Dramatically Worse Prognosis for Head and Neck Cancer: An examination of 20,915 Patients. Cancer; in press.

24. Panagreas KS, Schrag D, Riedel E, Bach PB, Begg CB (2003) The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med 139: 658–665.

25. Casson AG, van Lanschot JJ (2005) Improving outcomes after esophagectomy: the impact of operative volume. J Surg Oncol 92: 262–266.

26. Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, et al. (2008) Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg 12: 731–738.

27. Gutierrez JC, Kasirira N, Salloum RM, Franceschi D, Koniaris LG (2007) Surgery for rectal cancer performed at teaching hospitals improves survival and preserves continence. J Gastrointest Surg 11: 1441–1448. discussion 1448–1450.

28. Meguid RA, Brooke BS, Chang DC, Sherwood JT, Brock MV, et al. (2008) Are surgical outcomes for lung cancer resections improved at teaching hospitals? Ann Thorac Surg 85: 1015–1024. discussion 1024–1015.

29. Riall TS, Eshbach KA, Townsend CM Jr, Nealon WH, Freeman JL, et al. (2007) Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg 11: 1242–1251. discussion 1251–1242.

30. Petrelli NJ (2008) Not Just Another Article on Cancer Surgery Volume and Patient Outcomes. J Clin Oncol.